Table 3.
Consequences of psoriasis on outcomes in axSpA patients in multivariable analysis at 6 years of follow-up (N=589) and over 6 years of follow-up (N=708)
| Multivariable analysis at 6 years of follow-up: effect estimate (95% CI) (N=589) | Over 6 years: linear mixed-effects model: multivariable effect estimate (95% CI) (N=708) | |
| Key outcomes | ||
| ASDAS-CRP | 0.05 (−0.08 to 0.18) | 0.01 (−0.05 to 0.07) |
| HAQ-AS(0–3) | 0.05 (−0.05 to 0.14) | −0.003 (−0.04 to 0.03) |
| Other outcomes | ||
| BASDAI (0–100) | −3.52 (−16.85 to 9.82) | 0.76 (−0.09 to 1.62) |
| BASFI (0–100) | 3.10 (−1.31 to 7.50) | −0.36 (−1.82 to 1.09) |
| ASQoL (0–18) | 2.10 (−0.65 to 4.84) | 0.07 (−0.19 to 0.33) |
| SF36 | ||
| Physical Component Summary (0–100) | 0.69 (−5.97 to 7.35) | 0.31 (−0.23 to 0.85) |
| Mental Component Summary (0–100) | −2.39 (−7.45 to 2.67) | 0.14 (−0.64 to 0.92) |
| Work loss (days per year) | 273.73 (−1070.26 to 1617.72) | |
| Tender joint count (0–53) | −3.78 (−10.92 to 3.37) | −0.10 (−0.83 to 0.64) |
| Swollen joint count (0–28) | −0.07 (−0.22 to 0.07) | 0.09 (0.08 to 0.16) |
| MASES enthesitis index (0–13) | −0.10 (−0.87 to 0.68) | 0.25 (−0.02 to 0.52) |
| CRP (mg/L) | 3.50 (−9.60 to 16.61) | 0.47 (−0.43 to 1.37) |
| mSASSS* (0–72) | −0.54 (−1.60 to 0.51) | 0.35 (0.03 to 0.68) |
| Modified New York radiographic criteria during follow-up (local reading) | OR: 1.57 (0.22 to 11.71) | OR: 1.45 (0.56 to 3.73) |
| NSAIDs intake since last visit | OR: 1.14 (0.64 to 2.06) | OR: 0.95 (0.60 to 1.49) |
| Current csDMARDs intake | OR: 1.31 (0.45 to 3.74) | OR: 1.27 (0.60 to 2.66) |
| Methotrexate intake at least once during follow-up | OR: 2.31 (1.09 to 4.97) | OR: 2.38 (0.90 to 6.31) |
| bDMARDs intake at least once during follow-up | OR: 1.90 (0.99 to 3.69) | OR: 0.82 (0.34 to 1.99) |
For each outcome of interest, the effect of psoriasis (yes/no) is reported after adjustment on variables associated with the outcome of interest in univariable tests (according to a p<0.20).
Values in bold are significant values at p-value <0.05 in multivariable analyses at 6 years and over 6 years.
*Last assessment at year 5.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-C reactive protein; ASQoL, Ankylosing Spondylitis Quality of Life Scale; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARDs, biological DMARDs; csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs; HAQ-AS, Health Assessment Questionnaire for axSpA; MASES, Maastricht Ankylosing Spondylitis Enthesis score; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; NSAIDs, non-steroidal anti-inflammatory drugs; SF36, Short Form 36 Health Survey.